Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIPTM technology.

van Beek, Nina; Krüger, Stine; Fuhrmann, Tarek; Lemcke, Susanne; Goletz, Stephanie; Probst, Christian; Komorowski, Lars; Di Zenzo, Giovanni; Dmochowski, Marian; Drenovska, Kossara; Horn, Michael; Jedlickova, Hana; Kowalewski, Cezary; Medenica, Ljiljana; Murrell, Dedee; Patsatsi, Aikaterini; Geller, Shamir; Uzun, Soner; Vassileva, Snejina; Zhu, Xuejun; ... (2020). Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIPTM technology. (In Press). Journal of the American Academy of Dermatology Elsevier 10.1016/j.jaad.2020.01.049

[img] Text
1-s2.0-S019096222030133X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (15MB) | Request a copy

BACKGROUND The current standard in the serological diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIPTM mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence (IF). METHODS Sera from 749 consecutive, prospectively recruited, direct IF positive AIBD patients from 13 international study centers were analyzed independently and blinded using (i) a BIOCHIPTM mosaic including primate esophagus, salt-split skin, recombinant BP180 NC16A and gliadin GAF3x as well as HEK293 cells expressing recombinant desmoglein1, desmoglein3, type VII collagen, and BP230 C-terminus and (ii) the conventional multistep approach of the Department of Dermatology, University of Lübeck. RESULTS In 731 of 749 sera (97.6%) specific autoantibodies could be detected using the BIOCHIPTM mosaic, similar to the conventional procedure (725 cases, 96.8%). Cohens κ for both serological approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the two approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIPTM mosaic. LIMITATIONS Laminin 332 and laminin γ1 are not represented on the BIOCHIPTM mosaic. CONCLUSIONS The BIOCHIPTM mosaic is a standardized, time- and serum-saving approach that further facilitates the serological diagnosis of AIBD.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Horn, Michael


600 Technology > 610 Medicine & health








Karin Balmer

Date Deposited:

24 Feb 2020 13:05

Last Modified:

24 Feb 2020 13:13

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

autoimmune bullous diseases biochip immunofluorescence pemphigoid pemphigus




Actions (login required)

Edit item Edit item
Provide Feedback